JPRN-UMIN000005252已完成未知
Candesartan/Hydrochlorothiazide Versus High-dose Candesartan for the Clinical Assessment of N-terminal pro-B Type Natriuretic Peptide Levels and Cardio-renal Protective Effects: A comparative study - J-CHANCE
Juntendo University School of Medicine, Department of Cardiovascular Medicine0 个研究点目标入组 100 人开始时间: 2011年3月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with a history of hypersensitivity to the study drugs 2. Patients with a history of hypersensitivity to thiazide or thiazide-like diuretics 3. Patients with chronic renal failure (serum creatinine => 2.0 mg/dL) 4. Patients with anuria or on dialysis 5. Patients with acute renal failure 6. Patients whose levels of sodium and/or potassium are obviously low 7. Patients who are pregnant, possibly pregnant, or lactating
研究者
相似试验
已完成
不适用
Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVHEssential HypertensionLeft Ventricular HypertrophyNCT00607633AstraZeneca686
已完成
4 期
A comparison of losartan/hydrochlorothiazide vs high-dose angiotensin II receptor blocker(ARB) for uncontrolled hypertensive patientsHypertensionJPRN-UMIN000001389Kobe hypertensive study group193
已完成
4 期
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe HypertensionHypertensionNCT01012479Takeda107
进行中（未招募）
不适用
EFFECTS OF CANDESARTAN CILEXETIL VS STANDARD THERAPY ON SERUM LEVELS OF BRAIN NATRIURETIC PEPTIDE IN PATIENTS SUFFERING FROM CHRONIC HEART FAILURE WITH DEPRESSED AND PRESERVED SYSTOLIC FUNCTIOCHRONIC HEART FAILUREMedDRA version: 9.1Level: HLTClassification code 10024120Term: Left ventricular failuresEUCTR2005-001306-87-ITTAKEDA1,500
进行中（未招募）
不适用
Candesartan added Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters.An open, non-controlled and multicentre trialHeart failureEUCTR2004-003962-14-DETakeda Pharma GmbH